Recent Updates
Recently added Catalysts

Artelo Biosciences, Inc.

ARTLFDA catalysts, PDUFA dates & pipeline intelligence
$1.39
▼ -0.06 · -4.14%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ARTL financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.3052W HIGH $179.19
Volume
51.96 K
Value Traded
71.13 K
Short % Float
2.95%
Days to Cover
1.0
-32.85%Week
-45.7%1 Month
-77.68%3 Month
-87.02%6 Month
-96.99%1 Year
-99.92%5 Year
-99.89%All Time

Cash Data

Unlock ARTL cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.30 M
EPS (TTM)
-12.08
P/E Ratio
-
Ent. Value
-3.13 M
Total Shares
937.18 K
Float Shares
940.00 K
Insiders
0.06%
Institutions
3.22%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout
ART27.13
glaucoma, ocular hypertension
Phase 2Small MoleculesOphthalmology
Unlock every ARTL catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ARTL Catalyst Timeline

Dated clinical, regulatory and corporate events for Artelo Biosciences, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Artelo Biosciences, Inc.

419Total events
11Upcoming
44Tier-1 (high impact)
2018 to 2038Coverage

Upcoming catalysts 2

T2First Patient Dosed
Subscribe to view catalyst details
ART26
T2Trial Initiation
Subscribe to view catalyst details
ART26

Event history 50

●Quarterly UpdateCorporate
Q3 2026 business update and financial results reported
▲Preclinical PoCART27Preclinical
ART27.13 monotherapy ~20% and ~40% with semaglutide weight loss in diet-induced obesity model
obesitysource ↗
▲Patent GrantedART27IP / Competition
Notices of Allowance received in US and Japan for ART27.13 commercial formulation claims
◆Oral PresentationART26Presentation
ART26.12 data presentation at IASP 2026 World Congress on Pain
▲Preclinical PoCART27Preclinical
ART27.13 reduced mechanical allodynia and thermal hyperalgesia in nonclinical paclitaxel-induced peripheral neuropathy model
chemotherapy-induced neuropathic painsource ↗
●Oral PresentationART27Presentation
Oral presentation of preclinical ART27.13 data in paclitaxel-induced peripheral neuropathy at IASP 2026 World Congress on Pain
chemotherapy-induced neuropathic painsource ↗
▲Composition Patent FiledART27IP / Competition
Artelo files provisional patent application covering ART27.13 for obesity, alone and with GLP-1 receptor agonists
obesitysource ↗
▲Additional DataART27Clinical Data
New DIO-2 findings: appetite suppression, improved oral glucose tolerance, increased bone mineral density, lipid reductions
diet-induced obesitysource ↗
▲Preclinical PoCART27Preclinical
Additional DIO-2 nonclinical findings: combination with semaglutide improved oral glucose tolerance and increased bone mineral density
obesitysource ↗
▲Preclinical PoCART27Preclinical
Previously reported DIO-2 results: ART27.13 monotherapy ~20% weight loss, comparable to semaglutide
obesitysource ↗
Unlock the full ARTL catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ARTL actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-10ART26.12 Phase 1 data presentation Phase 1
Unlock 3 more ARTL historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Unlock the ARTL pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ARTL program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
ART27.13 cancer-related anorexiaPhase 22026-08-17more than 60% of participants; all patients taking the highest dose; +6% weight gain over 12 weeks; ~5% weight loss on placeboRead MoreArtelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 StudiesRead More
Scroll for more · summaries link to the source press release
Unlock every ARTL trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ARTL insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
FAVORITO TAMARA ADirectorBuyConversion 0 $0.00 05/01/2025
Unlock the full ARTL insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in ARTL for Q3 2026.
Unlock every fund holding ARTL
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ARTL
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see ARTL ownership
Insider and institutional ownership, quarter by quarter.

ARTL Short Interest

Shares sold short, counted twice a month.

2.95%
Short % of Float
of tradable shares sold short
27.7K
Shares Sold Short
-20.2% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
38.6K
Avg Daily Volume
the average used for days to cover
Unlock ARTL short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock ARTL option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ARTL option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ARTL options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ARTL ranks across every disease it competes in

Competitive Position is a premium feature
See how ARTL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ARTL News

ARTL
Nov 12, 2026
ARTLGeneral

Artelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial Results

Artelo Biosciences reported a positive business update for Q3 2026, highlighting significant advancements in its drug candidates. ART27.13 demonstrated up to 40% weight loss in combination with semaglutide, while ART26.12 is set to enter Phase 1 trials. The company also strengthened its intellectual property portfolio with new patents.

Read more →
ARTL
Oct 29, 2026
ARTLConferences/Events

Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain

Artelo Biosciences announced it will present data on ART27.13's potential to treat chemotherapy-induced neuropathic pain at the IASP 2026 World Congress. The ongoing Phase 2 CAReS trial includes pain endpoints to evaluate ART27.13's efficacy. Nonclinical studies showed significant reductions in pain sensitivity, indicating promising therapeutic applications.

Read more →
ARTL
Oct 26, 2026
ARTLConferences/Events
▼ -13.7%on this newsshared move

Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain

Artelo Biosciences will present ART26.12, its first-in-human FABP5 inhibitor, at the IASP 2026 World Congress on Pain. This selective FABP5 inhibitor aims to provide a novel, non-opioid approach to pain management. Initial studies show promising safety and efficacy, particularly for chemotherapy-induced peripheral neuropathy. The company plans to initiate a Phase 1 multiple ascending dose study soon.

Read more →
ARTL
Oct 7, 2026
ARTLConferences/Events

Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

Artelo Biosciences has been selected to present at BIO-Europe 2026, showcasing its clinical advancements, particularly with the FABP5 inhibitor ART26.12. The presentation will highlight promising data from clinical studies, including safety and efficacy in treating neuropathic pain and osteoarthritis. This event marks a significant opportunity for Artelo to engage with potential partners and expand its business development efforts.

Read more →
ARTL
Sep 23, 2026
ARTLGeneral
▲ +76.1%on this news

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

Artelo Biosciences has filed a provisional patent for ART27.13, targeting obesity treatment both as a monotherapy and in combination with GLP-1 receptor agonists like semaglutide. Recent studies show ART27.13 led to significant weight loss and improved metabolic parameters in obese mice. The findings suggest a broader role for ART27.13 in weight and metabolic regulation, potentially enhancing existing therapies.

Read more →
ARTL
Sep 16, 2026
ARTLPhases
▼ -29.8%on this news

Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

Artelo Biosciences reported that its oral drug ART27.13 resulted in a 20% weight loss in obese mice, matching semaglutide's effects. When combined with semaglutide, the weight loss reached approximately 40%. The findings suggest ART27.13 may act as a metabolic regulator, specifically targeting obesity without affecting lean animals.

Read more →
ARTL
Sep 8, 2026
ARTLConferences/Events

Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Artelo Biosciences, a clinical-stage pharmaceutical company, announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. CEO Gregory D. Gorgas will present on September 11, 2026, and the company will hold one-on-one meetings with investors during the event. Artelo focuses on developing treatments for various conditions, including cancer and pain.

Read more →
ARTL
Aug 27, 2026
ARTLGeneral
▼ -7%on this news

Artelo Biosciences Announces Reverse Stock Split

Artelo Biosciences has announced a 1-for-9 reverse stock split to improve the marketability and liquidity of its common stock. The split will take effect on August 31, 2026, with no fractional shares issued. Shareholders will retain their ownership percentage, and all outstanding warrants will adjust accordingly.

Read more →
ARTL
Aug 20, 2026
ARTLFDA Updates

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

Artelo Biosciences announced a notice of allowance from the Japanese Patent Office for its patent application regarding ART27.13, a dual cannabinoid agonist. This patent aligns with protections already granted in the U.S. and Europe, extending the drug's market potential until 2041. ART27.13 is currently in Phase 2 trials for cancer-related anorexia and glaucoma, showing promising early results.

Read more →
ARTL
Aug 17, 2026
ARTLPhases
▼ -8.8%on this newsshared move

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

Artelo Biosciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its investigational drug ART27.13, which is currently in two Phase 2 studies. This patent covers the intended commercial formulation of ART27.13, expected to extend protection until 2041. The drug shows promise in treating cancer-related anorexia and glaucoma, with positive interim results reported.

Read more →
ARTL
Aug 13, 2026
ARTLGeneral

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

Artelo Biosciences provided a business update and reported its Q2 2026 financial results, highlighting advancements in its clinical programs. The company is preparing to initiate a Phase 1 study for ART26.12, which has shown favorable safety and efficacy data. Additionally, ART27.13 has demonstrated promising interim results in improving body weight and activity in cancer patients. Despite a net loss of $2.4 million, Artelo remains optimistic about its future prospects.

Read more →
ARTL
Aug 10, 2026
ARTLPhases

Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma

Artelo Biosciences has announced the enrollment of the first patient in its Phase 2 clinical trial, the DREAM study, evaluating ART27.13 for glaucoma treatment. This study aims to assess the efficacy of ART27.13, a synthetic cannabinoid, in lowering intraocular pressure. Initial results are anticipated in Q4 2026, with funding provided by Glaucoma UK and the HSC R&D Division.

Read more →
ARTL
Jul 22, 2026
ARTLGeneral

New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition

A recent analysis published in the British Journal of Clinical Pharmacology reveals that widely sold non-prescription CBD products lack therapeutic efficacy due to inadequate dosing. Artelo's proprietary formulation, ART12.11, aims to enhance bioavailability and address these limitations. The study underscores the importance of evidence-based drug development in optimizing CBD treatments.

Read more →
ARTL
Jul 16, 2026
ARTLPhases

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions

Artelo Biosciences announced promising results from a nonclinical study of ART26.12, a FABP5 inhibitor, showing significant pain relief in osteoarthritis comparable to naproxen, but with less gastric damage. The findings suggest ART26.12 could provide a safer alternative for chronic pain management. Clinical trials for ART26.12 are set to begin in Q4 2026.

Read more →
ARTL
Jul 14, 2026
ARTLGeneral
▲ +10.5%on this newsshared move

Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026

Artelo Biosciences has reminded shareholders to vote in advance of its Annual Meeting on July 17, 2026. The company emphasizes the importance of submitting proxies to establish quorum and efficiently conduct business. Shareholders are encouraged to review proxy materials and participate in the voting process.

Read more →
ARTL
Jul 13, 2026
ARTLPhases

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Artelo Biosciences has announced positive results from nonclinical studies of ART27.13, a cannabinoid receptor agonist, in treating neuropathic pain associated with paclitaxel chemotherapy. The findings suggest that ART27.13 may have broader applications in cancer supportive care, particularly for patients suffering from anorexia cachexia syndrome. Interim results from the CAReS Phase 2 clinical study also indicate improvements in body weight and activity levels.

Read more →
ARTL
Jul 1, 2026
ARTLPhases

Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

Artelo Biosciences announced promising preclinical data for ART26.12, a selective FABP5 inhibitor, showing its potential to alleviate neuropathic pain associated with spinal cord injury. The findings, presented at a symposium in France, suggest ART26.12 could serve as a novel, non-opioid analgesic. The company emphasizes the need for effective treatments in chronic pain management.

Read more →
ARTL
Jun 30, 2026
ARTLConferences/Events

Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026

Artelo Biosciences presented findings at the ICRS 2026 Annual Symposium, highlighting the potential of its FABP5 inhibitor, ART26.12, in modulating lipid-signaling pathways across various disease models. The research indicates a mechanistic link involving linoleic acid, suggesting broad therapeutic applications. The company emphasizes the drug's favorable safety profile and its potential in treating conditions like chemotherapy-induced peripheral neuropathy.

Read more →
ARTL
Jun 29, 2026
ARTLPhases

Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026

Artelo Biosciences presented promising Phase 1 clinical data for ART26.12, a selective FABP5 inhibitor, at the ICRS 2026 Annual Symposium. The study showed a favorable safety profile and predictable pharmacokinetics in healthy volunteers. Additionally, new biomarker analyses indicated potential indicators of target engagement, supporting further clinical development of ART26.12.

Read more →
ARTL
Jun 10, 2026
ARTLPhases

Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success

Artelo Biosciences presented promising data on its lead candidate ART26.12 at a conference, highlighting a low-risk metabolite profile from a recent clinical study. The findings suggest that the majority of drug-related exposure comes from the parent compound, indicating a favorable pharmacokinetic profile. This could streamline future development and reduce risks associated with drug metabolism.

Read more →

About Artelo Biosciences, Inc.

Solana Beach, CA 7 employees artelobio.com
Headquarters505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA, 92075
Founded2011
BIOPHARMAWATCH ELITE
Trade the next ARTL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime